普米克令舒联合孟鲁司特治疗小儿哮喘的有效性分析

Efficacy of Pulmicort combined with montelukast in the treatment of childhood asthma

目的:评价普米克令舒联合孟鲁司特治疗小儿哮喘的有效性。方法:2019年1月-2021年1月收治小儿哮喘患儿106例,随机综合平衡法分为两组,各53例。参照组采取普米克令舒治疗;研究组采取普米克令舒联合孟鲁司特治疗。比较两组治疗效果。结果:研究组治疗总有效率高于参照组,差异有统计学意义(P<0.05);研究组治疗后白细胞介素-17(IL-17)、超敏C反应蛋白(hs-CRP)及肿瘤坏死因子-α(TNF-α)水平均低于参照组,差异有统计学意义(P<0.05);研究组气促、喘鸣音、咳嗽、喘息等症状消失时间均短于参照组,差异有统计学意义(P<0.05)。结论:给予小儿哮喘患儿普米克令舒联合孟鲁司特治疗,具有更为显著的效果,可促进临床症状尽快消失,进而降低炎性因子水平。

Objective:To explore the efficacy of Pulmicort combined with montelukast in the treatment of childhood asthma.Methods:From January 2019 to January 2021,106 children with asthma were selected.They were randomly divided into two groups with 53 cases in each group using the comprehensive balance method.The control group was treated with Pulmicort.The study group was treated with Pulmicort combined with montelukast.We compared the therapeutic effects of the two groups.Results:The total effective rate of the study group was higher than that of the reference group,the difference was statistically significant(P<0.05).In the study group,after treatment,interleukin-17(IL-17),high-sensitivity C-reactive protein(hs-CRP)and tumor necrosis factor-α(TNF-α)were lower than the reference group,the difference was statistically significant(P<0.05).In the study group,the disappearance time of symptoms such as shortness of breath,wheezes,cough and gasp was shorter than that in the reference group,the difference was statistically significant(P<0.05).Conclusion:The efficacy of Pulmicort combined with montelukast in the treatment of childhood asthma is significant,it can promote the disappearance of clinical symptoms as soon as possible,and then reduce the level of inflammatory factors.